Progyny, Inc.
Financials
Valuation Metrics
Progyny, Inc.'s Market Cap is $2.08B. At end of 2025 it was $2.19B. Ranked #2003 of 3,121 in US market (top 64%), #762 of 1,463 on NASDAQ (top 52%), #121 of 205 in Health Care Equipment & Services (top 59%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.08B | US#2,003/3,121 Sec#121/205 |
| Revenue | $1.31B | US#1,725/3,121 Sec#107/205 |
| Net Income | $79M | US#1,723/3,121 Sec#86/205 |
| Total Assets | $716M | US#2,621/3,121 Sec#143/205 |
| Net Assets | $453M | US#2,297/3,121 Sec#118/205 |
| Employees | 835 | US#2,068/3,121 Sec#145/205 |
| Value | ||
| P/E | 26.47x | US#1,462/3,121 Sec#53/205 |
| P/B | 4.59x | US#2,136/3,121 Sec#125/205 |
| PEG | 0.55x | US#640/3,121 Sec#28/205 |
| P/S | 1.59x | US#1,071/3,121 Sec#72/205 |
| EV/EBITDA | 15.39x | US#1,569/3,121 Sec#64/205 |
| FCF Yield | 10.47% | US#533/3,121 Sec#21/205 |
| Profitability | ||
| ROE | 17.35% | US#737/3,121 Sec#32/205 |
| ROA | 10.98% | US#411/3,121 Sec#24/205 |
| Op. Margin | 8.55% | US#1,713/3,121 Sec#87/205 |
| Revenue Growth | 5.54% | US#1,751/3,121 Sec#125/205 |
| Earnings Growth | 48.02% | US#534/3,121 Sec#27/205 |
| Financial Health | ||
| Debt Ratio | 57.93% | US#656/3,121 Sec#73/205 |
| Total Debt | $27M | US#2,714/3,121 Sec#166/205 |
| FCF | $218M | US#1,341/3,121 Sec#77/205 |
| Cash | $153M | US#1,950/3,121 Sec#119/205 |
| Current Ratio | 2.14x | US#1,154/3,121 Sec#104/205 |
| Net Debt/EBITDA | -0.99x | US#285/3,121 Sec#22/205 |
| Performance | ||
| 1Y Return | 20.47% | US#1,035/3,121 Sec#80/205 |
| 1M Return | 6.27% | US#485/3,121 Sec#59/205 |
| From 52W High | -17.96% | US#1,376/3,121 Sec#94/205 |
| 1Y MDD | -42.65% | US#2,144/3,121 Sec#125/205 |
| Trading | ||
| Volume | 1,999,584 shares | US#1,583/3,121 Sec#97/205 |
| Trading Value | $54M | US#1,817/3,121 Sec#126/205 |
| Per Share | ||
| EPS | $1.02 | US#1,669/3,121 Sec#89/205 |
| BPS | $5.91 | US#2,203/3,121 Sec#138/205 |
Company Info
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.